Biotech

News

Bar graph of gold coins increasing from left to right, with plants growing out the top

Crystalys emerges with $205m, and other biofinancings

Recent biotech financings include big rounds for Crystalys and Star Therapeutics, with Sparrow, Avenzo, and Aerska also raising new funds.

News

Lila Sciences' $235m first round, and other biofinancings

Recent biotech financings include big rounds for Lila Sciences, Odyssey, and Ollin, with ARTHEx, Dualitas, and YolTech also in on the action.

News

Heather Turner, LB Pharma's chief executive.

After a long biotech IPO lull, LB Pharma chances its arm

After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.

News

Treeline's $200m Series A extension, and other biofinancings

Recent biotech financings include a $200m round for Treeline, with Enveda, Wugen, CHARM Therapeutics, and MRM Health also in on the action.

Market Access

Biotech ≠ tech: Why venture capital needs a new playbook for...

Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1

News

Strand raises $153m for RNA meds, and other bio financings

Recent financings in biotech include a $153m Series B for programmable mRNA developer Strand, plus rounds for Artbio, Minghui, and Chai Discovery.

Crystalys emerges with $205m, and other biofinancings

Lila Sciences' $235m first round, and other biofinancings

After a long biotech IPO lull, LB Pharma chances its arm

Treeline's $200m Series A extension, and other biofinancings

Biotech ≠ tech: Why venture capital needs a new playbook for...

Strand raises $153m for RNA meds, and other bio financings

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

Biotech

Editor's Picks